Barclays PLC Acquires 36,071 Shares of Paysign, Inc. (NASDAQ:PAYS)

Barclays PLC increased its position in Paysign, Inc. (NASDAQ:PAYS) by 327.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,090 shares of the company’s stock after purchasing an additional 36,071 shares during the period. Barclays PLC owned approximately 0.09% of Paysign worth $173,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of PAYS. Algert Global LLC bought a new position in Paysign during the 2nd quarter valued at about $46,000. SG Americas Securities LLC bought a new position in Paysign during the 3rd quarter valued at about $43,000. The Manufacturers Life Insurance Company bought a new position in Paysign during the 2nd quarter valued at about $66,000. American Century Companies Inc. bought a new position in Paysign during the 2nd quarter valued at about $92,000. Finally, Bard Associates Inc. purchased a new stake in shares of Paysign during the 3rd quarter valued at about $103,000. Institutional investors own 25.89% of the company’s stock.

Insider Buying and Selling at Paysign

In related news, insider Matthew Louis Lanford sold 25,360 shares of Paysign stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $3.96, for a total transaction of $100,425.60. Following the completion of the sale, the insider now owns 109,731 shares of the company’s stock, valued at $434,534.76. The trade was a 18.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Mark Newcomer sold 40,000 shares of Paysign stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $3.24, for a total value of $129,600.00. Following the transaction, the chief executive officer now owns 9,296,886 shares of the company’s stock, valued at approximately $30,121,910.64. This represents a 0.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 885,447 shares of company stock worth $2,836,034 over the last quarter. Insiders own 23.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Lake Street Capital assumed coverage on shares of Paysign in a research report on Friday, December 20th. They set a “buy” rating and a $6.00 price target for the company. Barrington Research reaffirmed an “outperform” rating and set a $7.00 price target on shares of Paysign in a research report on Monday, November 4th.

Paysign Stock Down 1.0 %

Shares of PAYS opened at $2.86 on Thursday. The business has a fifty day moving average of $3.17 and a 200 day moving average of $3.91. Paysign, Inc. has a 52-week low of $2.65 and a 52-week high of $5.59. The company has a market cap of $153.15 million, a PE ratio of 19.07 and a beta of 0.95.

Paysign (NASDAQ:PAYS) last released its earnings results on Tuesday, November 5th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.02. The business had revenue of $15.26 million for the quarter, compared to analyst estimates of $14.96 million. Paysign had a return on equity of 30.64% and a net margin of 14.28%. During the same quarter last year, the firm posted $0.02 earnings per share. As a group, research analysts anticipate that Paysign, Inc. will post 0.21 earnings per share for the current fiscal year.

Paysign Company Profile

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.